Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen's Phosphate Binder Loss May Be Genzyme's Gain

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed

You may also be interested in...



Amgen/Takeda To Re-start Motesanib Lung Cancer Trial

Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee

Amgen/Takeda To Re-start Motesanib Lung Cancer Trial

Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee

Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Related Content

Topics

UsernamePublicRestriction

Register

PS004053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel